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Introduction
Target and organ at risk (OAR) delineation for intensity modulated radiation therapy (IMRT) treatment planning in the head-and-neck (H&N) region can be both challenging and time consuming. Accuracy is paramount for effective optimization during the inverse planning process. Assignment of the appropriate margin(s) for planning target volume (PTV) expansion to account for immobilization and localization uncertainties often results in portions of the PTV being located in regions of electronic disequilibrium. With the variations in the expected external beam surface dose calculations for various situations given by Fraass et al, 1 it would seem prudent to apply bolus material for any PTV that is delineated in the build-up region. However, given the skin tolerance to radiation, physicians are often reluctant to follow this approach and may make clinical decisions with respect to target coverage based on the calculated isodose distributions without a full understanding of the inaccuracies inherent in treatment planning system (TPS) algorithms.
The aforementioned inaccuracies appear to be compounded by the IMRT process and in 2002 Lee et al 2 attempted to explain the increase in skin toxicity for their H&N patients undergoing IMRT. While they found that the skin dose could be reduced by considering the skin a sensitive structure during the optimization process, they did note that there was an overestimation of skin dose by the TPS. In 2004, Thomas and Hoole 3 suggested that IMRT delivery is not the cause of increased skin dose but that increased fluence, generated during optimization, being delivered in the surface region for scenarios where the PTV extends near the skin, is the real cause. In 2005, Chung et al 4 demonstrated "significant discrepancies" between calculation and measurement for doses from the surface to about 2 mm in depth, and further indicated that the TPS overestimated the surface dose. From the tables presented by Court and Tishler 5 in 2007, when they evaluated the effects on calculated doses at the skin and shallow targets for different IMRT planning methods, it can be seen that the TPS again overpredicts the skin dose for PTVs defined at the skin surface. Finally, in 2011, Shiau et al 6 used a "ball phantom" to measure surface dose and compare with the TPS values as a function of "shrinkage margin" of the target from the skin. They concluded that "the accuracy of dose calculation in the superficial region for a TPS does not depend on different shrinkage margins, but on the dose calculation algorithm." While the studies above indicate that, in general, TPS surface dose for IMRT is typically overestimated, no attempt has been made to guide the physician during the IMRT treatment planning process with respect to PTV-toskin proximity, associated dose uncertainties, or the effects on plan quality. To this end, the goal of this work was to evaluate PTV-to-skin proximity versus plan quality as well as the effects of calculation grid voxel size on dose calculation uncertainty in the surface region, and to provide appropriate parameters for use during planning and the approximate levels of uncertainty for variations.
Methods and materials
Computed tomographic (CT) data were obtained for the cephalic-most 16 sections of an anthropomorphic phantom (Alderson Radiation Therapy Phantom; Radiology Support Devices, Long Beach, CA) at a slice thickness of 2.5 mm and imported into the Eclipse treatment planning system (version 10.0, Varian Medical Systems, Palo Alto, CA). A right-sided ipsilateral clinical target volume (CTV) with the lateral border being 5 mm from the skin surface was delineated for planning purposes (Fig 1A) . Five different PTVs were generated using 5-mm expansion from the CTV in all directions except laterally, where distances from the skin surface of 5, 3, 2, 1, and 0 mm were used. A typical 6-MV, 7-field IMRT plan (gantry angles 135, 30, 330, 300, 270, 245, and 180 degrees) was generated for step-and-shoot delivery using the analytic anisotropic algorithm. Optimization was performed such that 60 Gy would be delivered at 2 Gy/fraction with a minimum of 95% of the PTV receiving the prescription dose with calculations being performed with a matrix size of 2 mm 3 (our clinically used grid size).
There were no additional critical structures or organs at risk to complicate the optimization process for this study, with the only variable being PTV-to-skin proximity. Once an acceptable plan was generated, the final dose calculations were repeated for grid sizes of 1, 3, and 5 mm 3 . Reoptimization was not performed. For each plan, 9 point-dose values were obtained just inside the phantom surface using the zoom function and point-dose measurement tool in the TPS software. These point-dose measurements correspond to the intersecting lines of a 2 cm × 2 cm grid associated with the central portion of the target, at the skin surface (Fig 1B) .
The phantom was placed on the couch of a Varian iX linear accelerator and aligned via cone beam CT (CBCT). Nine ultrathin thermoluminescent dosimeters (TLDs) (Harshaw Chemical Company, Solon, OH), each measuring 3 × 3 × 0.15 mm 3 , were placed on the phantom surface corresponding to the intersecting lines of the 2 cm × 2 cm grid mentioned above. The delivery sequences associated with the aforementioned planning scenarios were delivered and measured with the TLDs. Comparisons were made between measured and calculated dose values.
Plan quality was assessed by comparing conformality, homogeneity, and target coverage for each dose calculation grid size as a function of PTV-to-skin distance. The conformality index (CI) was defined as the ratio of the prescription isodose volume and the PTV. Homogeneity was assessed by evaluating the hot spot, defined as the maximum dose to 0.1 cc of PTV, for the same parameters. Target coverage was assessed by evaluating the shoulder of the associated dose-volume histogram (DVH) as well as the prescription isodose distribution.
In 2000, Mutic and Low 7 evaluated surface dose agreement between measurement and TPS values for serial tomotherapy delivery. They found that the TPS "…tended to overestimate doses within the first few millimeters below the surface." As we routinely utilize volumetric modulated arc therapy (VMAT) planning and delivery at our institution, the process above was repeated for VMAT plans generated using a 2-mm 3 
Results
Figures 2A and 2B illustrate the comparison of measured versus calculated average skin dose values, as a function of PTV-to-skin distance, for plans generated using a 5-, 3-, 2-, and 1-mm 3 calculation voxel size. The surface dose is overestimated by the TPS by approximately 21% and 9.5% for the 5-and 3-mm 3 voxel sizes, respectively. The surface dose appears to be accurately predicted (within 1%) for the 2-mm 3 calculation voxel size and the use of a voxel size of 1 mm 3 results in an underestimation of approximately 11%. As can be seen from the measured values, for the commonly "acceptable" calculation voxel sizes of 1-3 mm 3 , surface dose increases by an average of approximately 28% when decreasing the PTV-to-skin distance from 4 mm to 0 mm.
Plan conformality as a function of PTV-to-skin distance is illustrated in Fig 3A. It can be seen that a similar trend is evident for all plans with the CI improving as the PTV is moved away from the skin surface. For the clinically relevant calculation grid sizes (1, 2, and 3 mm 3 ) it appears that a CI of unity is reached at a PTV-to-skin distance between approximately 4 and 4.5 mm. To evaluate if the trend of improved conformality with increasing PTV-toskin distance is algorithm dependent, the final dose calculation was performed using a pencil beam algorithm with heterogeneity corrections made using the rudimentary equivalent tissue-air ratio method. An integer value for the size of the calculation grid is not given as an option in the clinically useful range; therefore, an intermediate grid size of 2.5 mm 3 was selected. As can be seen in Fig 3A, while the absolute value of the CI may differ, the trend appears to hold, regardless of the algorithm used. This phenomenon helps to illustrate the known difficulties of delivering dose to the build-up region.
Overall plan hot spot as a function of PTV-to-skin distance is illustrated in Fig 3B and again it can be seen that a similar trend is evident for all plans with the hot spot decreasing as the PTV is moved away from the skin surface. While the hot spot is lowest when the PTV is furthest from the skin surface, for the clinically relevant calculation grid sizes the hot spot falls below 110% of the Skin proximity for head-and-neck IMRT e23 prescription dose once the PTV-to-skin distance reaches approximately 4 mm. To assess if this trend is algorithm dependent, the results from the pencil beam calculations were included. Again, it can be seen that the trend holds.
While all plans were normalized such that 95% of the PTV receives the prescription dose, it can be seen from the DVH in Fig 3C that target underdosage, depicted by the pronounced shoulder, is progressively greater as the PTV approaches the skin than that of the plan where the PTV is defined 5 mm from the surface. The underdosed volume is located in the build-up region, as expected, with the axial distance from the surface to the prescription isodose line being approximately 7.4, 5.9, 5.1, 3.9, and 3.8 mm for PTV-to-skin distances of 5, 3, 2, 1, and 0 mm, respectively. The plans represented in Fig 3C were generated using a 2-mm 3 calculation grid. Figure 4A illustrates the comparison for the VMAT plans generated using a 2-mm 3 calculation voxel size. The surface dose is accurately predicted by the TPS (within 1.2%). Skin proximity for head-and-neck IMRT e25 Conformality for the above VMAT plans as compared with the 7-field fixed-beam IMRT plans generated for the same voxel size is illustrated in Fig 4B. It can be seen that a similar trend is evident for all plans, with the CI improving as the PTV is moved away from the skin surface. It appears that a CI of unity is again reached at a PTV-to-skin distance between approximately 4 and 4.5 mm.
The hot spot as illustrated in Fig 4C decreases as the PTV is moved away from the skin surface. The VMAT hot spot falls below 110% of the prescription dose once the PTV-to-skin distance reaches approximately 4.5 mm. Figure 4D illustrates VMAT target underdosage depicted by the pronounced shoulder, being progressively greater as the PTV approaches the skin surface. The underdosed volume is located in the build-up region where the axial distance from the surface to the prescription isodose line is approximately 8.1, 5.9, 4.8, 3.8, and 3.1 mm for PTV-to-skin distances of 5, 3, 2, 1, and 0 mm, respectively. All plans represented in Figs 4A-D were generated using a 2-mm 3 calculation grid.
Discussion
The TPS dose calculation near the surface is a complex issue and is dominated by the classic "build up" effect demonstrated by a single beam percent depth dose curve and the "build down" effect for beams exiting the same region into a lower density medium (air in this case). However, clinicians rely on the TPS in part to help them determine the best course of radiation therapy delivery. This is particularly true with inverse planning for IMRT and an understanding of the input parameters is necessary for the planner to generate an acceptable dose distribution. It is assumed that target volume delineated in the surface region requires adequate dose coverage and there are many planning methods used to generate isodose distributions for targets approaching the skin surface. However, a detailed description of these methods is Skin proximity for head-and-neck IMRT e27 beyond the scope of this text. It is important to note that it is the accuracy of the resultant dose distributions that is of greatest importance as the adequacy of target coverage is determined by the clinician using information generated with the TPS. As shown in this work, the agreement between the calculated and measured values for surface dose varies as a function of dose calculation voxel size. Plan quality varies with PTV-to-skin proximity with degradation evident in all parameters assessed as the target approaches the surface. The optimization software is attempting to minimize the degree of underdosage but the lack of dose in the disequilibrium region is a physical phenomenon associated with energy deposition of highenergy photon beams. Entering beams do not achieve electronic equilibrium, tangential beams are without lateral equilibrium, and exiting beams lack typical backscatter in these regions. Altering the optimization methodology to increase dose to this region will invariably result in plan degradation in other regions. If the surface region is to be treated without the aforementioned degradation, the physical nature of the photon beam must be changed (eg, beam spoiler) or bolus material must be added to provide the appropriate dose build-up or equilibrium conditions. Dose calculation voxel size is variable for many reasons, one of which being calculation time. The larger the voxel size, the faster the calculation. Small voxels may be avoided in some clinics as they result in inordinately long calculation times. However, it can be seen in this work that the accuracy of surface dose prediction and plan quality vary as a function of calculation voxel size. It would seem intuitive that smaller voxel sizes would result in more favorable comparisons of surface dose because the larger voxels encompass larger volumes through the dose gradient near the surface, and the average value subsequently determined results in overestimation as compared with measured surface values. However, as can be seen in Fig 5, dose is calculated outside the phantom for approximately 2 voxels. Furthermore, because the dose values are artificially set to zero beyond 2 voxels by the TPS, the slope of the dose gradient outside the phantom is steepest for the smallest calculation voxel size. The profiles demonstrate this with the steepest gradient outside the phantom corresponding to the 1-mm 3 voxel size. Inside the phantom (tissue) the curves for the clinically useful calculation voxel sizes converge between 2 and 3 mm further demonstrating this effect as the entire voxel is contained within the phantom. Comparisons may be further complicated by the fact that the TLDs measuring 3 mm on a side may stretch across more than 1 voxel, but the resultant values are compared with point doses. Additionally, while the TLDs used are only 0.15-mm thick, they do contribute some build up. These measurement uncertainties are compounded by the determination of the surface boundary given the known artifacts in CT reconstruction of this region. While the 2-mm 3 calculation grid voxel size resulted in the best agreement with surface dose measurement, this fact should be used with caution as it is based on this Figure 5 Illustration of treatment planning system calculated dose in the skin-to-air boundary region for all calculation grid sizes. It can be seen that dose is calculated for approximately 2 voxels outside the phantom surface and therefore a more rapid dose fall-off is demonstrated for smaller calculation voxel sizes. Dose inside the phantom appears to increase at similar rates. e28 particular TPS, the existing algorithmic implementation, and beam energy. As such, for calculation grid sizes of 1-3 mm 3 TPS generated surface dose agreement with measurement can be expected to be within ± 10%. Combined with the measures of plan quality, these data may be used to generate reasonably accurate treatment plans. Table 1 summarizes the degree of TPS estimation of surface dose, plan conformality, and homogeneity as a function of PTV-to-skin distance, for the various calculation voxel sizes evaluated. It is also important to note that agreement between calculated and measured surface dose may vary for other systems and algorithmic implementations. However, if dose calculation accuracy is ensured, the aforementioned plan quality characteristics should remain unchanged.
In the interest of plan quality and accuracy, the authors would recommend the routine use of a 4-to 5-mm PTV-toskin distance for IMRT and VMAT treatment planning. Using a 2-mm 3 dose calculation grid results in a CI of approximately 1.01 and a "hot spot" of approximately 110%. Additionally, the shoulder of the target DVH is minimized, resulting in a higher minimum dose. For patients requiring a PTV-to-skin distance of less than this value, a 5-mm thick bolus should be constructed prior to CT acquisition. This does not necessarily mean that the skin will then receive the full prescription dose as dose to the skin would obviously be limited by target proximity. The dose distribution to the skin and the first few millimeters of tissue would be more accurate and the acquisition of center-specific skin dose as a function of volume from the TPS in the region directly adjacent to the target may then allow clinicians to arrive at meaningful guidelines for treatment planning and potential use during the optimization process.
For the TPS used in this study it appears that plan quality as a function of decreasing PTV-to-skin distance varies in the following ways: isodose conformality decreases; "hot spot" increases; and target coverage degrades. The TPS appears to overpredict surface dose for IMRT delivery for dose calculation voxel sizes N 2 mm 3 , underestimates for voxel sizes b2mm 3 , and accurately predicts the surface dose for a 2-mm 3 voxel size. All of the above appear to hold for VMAT planning and delivery. 
